vs

Side-by-side financial comparison of HARTE HANKS INC (HHS) and NeuroPace Inc (NPCE). Click either name above to swap in a different company.

HARTE HANKS INC is the larger business by last-quarter revenue ($39.9M vs $26.6M, roughly 1.5× NeuroPace Inc). HARTE HANKS INC runs the higher net margin — 5.5% vs -10.3%, a 15.8% gap on every dollar of revenue. On growth, NeuroPace Inc posted the faster year-over-year revenue change (23.9% vs -15.4%). NeuroPace Inc produced more free cash flow last quarter ($409.0K vs $-686.0K). Over the past eight quarters, NeuroPace Inc's revenue compounded faster (21.1% CAGR vs -6.4%).

Harte Hanks is a global marketing services company headquartered in Boston, Massachusetts. Harte Hanks services include analytics, strategy, marketing technology, creative services, digital marketing, customer care, direct mail, logistics, and fulfillment.

NeuroPace Inc is a medical technology company focused on developing and commercializing innovative implantable neurostimulation systems to treat neurological disorders, primarily drug-resistant epilepsy. Its core RNS System delivers personalized responsive stimulation to reduce seizure frequency, serving patients across North America and select global markets via partnerships with healthcare providers.

HHS vs NPCE — Head-to-Head

Bigger by revenue
HHS
HHS
1.5× larger
HHS
$39.9M
$26.6M
NPCE
Growing faster (revenue YoY)
NPCE
NPCE
+39.3% gap
NPCE
23.9%
-15.4%
HHS
Higher net margin
HHS
HHS
15.8% more per $
HHS
5.5%
-10.3%
NPCE
More free cash flow
NPCE
NPCE
$1.1M more FCF
NPCE
$409.0K
$-686.0K
HHS
Faster 2-yr revenue CAGR
NPCE
NPCE
Annualised
NPCE
21.1%
-6.4%
HHS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HHS
HHS
NPCE
NPCE
Revenue
$39.9M
$26.6M
Net Profit
$2.2M
$-2.7M
Gross Margin
77.4%
Operating Margin
-0.3%
-6.6%
Net Margin
5.5%
-10.3%
Revenue YoY
-15.4%
23.9%
Net Profit YoY
48.0%
EPS (diluted)
$0.30
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HHS
HHS
NPCE
NPCE
Q4 25
$39.9M
$26.6M
Q3 25
$39.5M
$27.4M
Q2 25
$38.6M
$23.5M
Q1 25
$41.6M
$22.5M
Q4 24
$47.1M
$21.5M
Q3 24
$47.6M
$21.1M
Q2 24
$45.0M
$19.3M
Q1 24
$45.4M
$18.1M
Net Profit
HHS
HHS
NPCE
NPCE
Q4 25
$2.2M
$-2.7M
Q3 25
$-2.3M
$-3.5M
Q2 25
$-335.0K
$-8.7M
Q1 25
$-392.0K
$-6.6M
Q4 24
$-5.3M
Q3 24
$142.0K
$-5.5M
Q2 24
$-27.8M
$-7.5M
Q1 24
$-171.0K
$-8.9M
Gross Margin
HHS
HHS
NPCE
NPCE
Q4 25
77.4%
Q3 25
77.4%
Q2 25
77.1%
Q1 25
77.0%
Q4 24
75.4%
Q3 24
73.2%
Q2 24
73.4%
Q1 24
73.6%
Operating Margin
HHS
HHS
NPCE
NPCE
Q4 25
-0.3%
-6.6%
Q3 25
1.3%
-9.5%
Q2 25
0.1%
-29.0%
Q1 25
-0.1%
-22.9%
Q4 24
-3.3%
-17.0%
Q3 24
4.0%
-20.1%
Q2 24
3.0%
-32.4%
Q1 24
0.8%
-41.6%
Net Margin
HHS
HHS
NPCE
NPCE
Q4 25
5.5%
-10.3%
Q3 25
-5.8%
-12.8%
Q2 25
-0.9%
-36.8%
Q1 25
-0.9%
-29.3%
Q4 24
-24.5%
Q3 24
0.3%
-25.9%
Q2 24
-61.8%
-39.0%
Q1 24
-0.4%
-49.2%
EPS (diluted)
HHS
HHS
NPCE
NPCE
Q4 25
$0.30
$-0.08
Q3 25
$-0.31
$-0.11
Q2 25
$-0.05
$-0.26
Q1 25
$-0.05
$-0.21
Q4 24
$-0.31
$-0.16
Q3 24
$0.02
$-0.19
Q2 24
$-3.84
$-0.26
Q1 24
$-0.02
$-0.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HHS
HHS
NPCE
NPCE
Cash + ST InvestmentsLiquidity on hand
$5.6M
$61.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$20.5M
$19.0M
Total Assets
$91.8M
$105.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HHS
HHS
NPCE
NPCE
Q4 25
$5.6M
$61.1M
Q3 25
$6.5M
$60.0M
Q2 25
$4.8M
$62.1M
Q1 25
$9.0M
$66.3M
Q4 24
$9.8M
$52.8M
Q3 24
$5.9M
$56.8M
Q2 24
$11.0M
$55.5M
Q1 24
$11.5M
$58.9M
Stockholders' Equity
HHS
HHS
NPCE
NPCE
Q4 25
$20.5M
$19.0M
Q3 25
$19.9M
$18.5M
Q2 25
$22.2M
$19.4M
Q1 25
$21.4M
$24.3M
Q4 24
$21.7M
$8.0M
Q3 24
$21.0M
$9.8M
Q2 24
$20.6M
$9.9M
Q1 24
$20.0M
$14.3M
Total Assets
HHS
HHS
NPCE
NPCE
Q4 25
$91.8M
$105.6M
Q3 25
$92.7M
$107.3M
Q2 25
$95.0M
$106.1M
Q1 25
$100.6M
$110.2M
Q4 24
$101.8M
$94.6M
Q3 24
$108.1M
$96.3M
Q2 24
$109.7M
$94.4M
Q1 24
$113.4M
$98.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HHS
HHS
NPCE
NPCE
Operating Cash FlowLast quarter
$737.0K
$506.0K
Free Cash FlowOCF − Capex
$-686.0K
$409.0K
FCF MarginFCF / Revenue
-1.7%
1.5%
Capex IntensityCapex / Revenue
3.6%
0.4%
Cash ConversionOCF / Net Profit
0.33×
TTM Free Cash FlowTrailing 4 quarters
$-4.5M
$-11.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HHS
HHS
NPCE
NPCE
Q4 25
$737.0K
$506.0K
Q3 25
$3.2M
$-1.9M
Q2 25
$-4.8M
$-2.1M
Q1 25
$-818.0K
$-7.5M
Q4 24
$4.0M
$-4.8M
Q3 24
$-2.9M
$-1.7M
Q2 24
$1.6M
$-3.9M
Q1 24
$-5.7M
$-7.5M
Free Cash Flow
HHS
HHS
NPCE
NPCE
Q4 25
$-686.0K
$409.0K
Q3 25
$2.2M
$-2.0M
Q2 25
$-5.1M
$-2.3M
Q1 25
$-923.0K
$-7.5M
Q4 24
$3.4M
$-4.8M
Q3 24
$-4.9M
$-1.8M
Q2 24
$926.0K
$-4.0M
Q1 24
$-6.2M
$-7.6M
FCF Margin
HHS
HHS
NPCE
NPCE
Q4 25
-1.7%
1.5%
Q3 25
5.5%
-7.2%
Q2 25
-13.1%
-9.6%
Q1 25
-2.2%
-33.4%
Q4 24
7.3%
-22.5%
Q3 24
-10.2%
-8.7%
Q2 24
2.1%
-20.6%
Q1 24
-13.7%
-42.1%
Capex Intensity
HHS
HHS
NPCE
NPCE
Q4 25
3.6%
0.4%
Q3 25
2.5%
0.1%
Q2 25
0.6%
0.7%
Q1 25
0.3%
0.2%
Q4 24
1.3%
0.2%
Q3 24
4.0%
0.5%
Q2 24
1.5%
0.3%
Q1 24
1.2%
0.6%
Cash Conversion
HHS
HHS
NPCE
NPCE
Q4 25
0.33×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
-20.76×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HHS
HHS

Fulfillment And Logistics Services$17.3M43%
Customer Care$13.7M34%
Other$8.9M22%

NPCE
NPCE

Segment breakdown not available.

Related Comparisons